Document Detail

Dose-dependent Effects of Ladostigil on Microglial Activation and Cognition in Aged Rats.
MedLine Citation:
PMID:  23325108     Owner:  NLM     Status:  Publisher    
The current study determined the effects of chronic treatment of aging rats with ladostigil, a cholinesterase (ChE) and monoamine oxidase (MAO) inhibitor, at doses of 1 and 8.5 mg/kg/day, on novel object recognition (NOR) and reference memory in the Morris water maze (MWM). A dose of (1 mg/kg/day) did not inhibit ChE or MAO but prevented the loss of NOR and reference memory in the MWM that occurs at 20.5 months of age. This anti-aging effect was associated with a reduction in the expression of CD11b, a marker of microglial activation, in the fornix and parietal cortex and restoration of microglial morphology to that in young adult rats. Ladostigil (8.5 mg/kg/day) inhibited brain ChE by ≈30 % and MAO A and B by 55-59 %, and had a similar, or greater effect than the low dose on microglia, but was less effective in preventing the decline in NOR. Ladostigil (8.5 mg/kg/day) may have caused too much cortical ChE inhibition and acetylcholine elevation at 16 months when NOR was intact. In support of this suggestion we showed that acute administration of ladostigil (8.5 mg/kg) worsened NOR at this age. However, at 20 months, when NOR was impaired and brain acetylcholine levels are 40 % below normal, ladostigil (8.5 mg/kg) reversed the memory deficit. Conclusion: Ladostigil (1 mg/kg/day) prevents the development of age-related memory deficits by a combination of immunomodulatory and antioxidant effects. A dose causing 30 % ChE inhibition is necessary in order to reverse existing memory deficits at 20 months of age.
Marta Weinstock; Corina Bejar; Donna Schorer-Apelbaum; Rony Panarsky; Lisandro Luques; Shai Shoham
Related Documents :
17597608 - Antithrombotic and hemostatic effects of a small molecule factor xia inhibitor in rats.
24995298 - Toxicity profile of a nutraceutical formulation derived from green mussel perna viridis.
12538808 - Antithrombotic properties of ssr182289a, a new, orally active thrombin inhibitor.
20731638 - The effect of low molecular weight heparin (enoxaparin) on enhanced coagulation induced...
1539168 - Induction of metallothionein by cadmium-metallothionein in rat liver: a proposed mechan...
9888628 - The development of addiction to d-amphetamine in an animal model: same principles as fo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-17
Journal Detail:
Title:  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology     Volume:  -     ISSN:  1557-1904     ISO Abbreviation:  J Neuroimmune Pharmacol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101256586     Medline TA:  J Neuroimmune Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Pharmacology, Institute of Drug Research, Hebrew University Medical Center, Ein Kerem, Jerusalem, 91120, Israel,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Curcumin Ameliorates the Neurodegenerative Pathology in A53T ?-synuclein Cell Model of Parkinson's D...
Next Document:  Genome-wide maps of polyadenylation reveal dynamic mRNA 3'-end formation in mammalian cell lineages.